First and Only US Pediatric human rabies Immune globulin Trial
Kedrion-Kamada Announce Study Met Its Primary Objective
First patient enrolled and treated in Kedrion’s CARES10 clinical study
Phase 3 study to assess efficacy, safety and pharmacokinetics of a 10% IVIg in the treatment of adult PID patients
Article by Prof. Farrugia and Daniela Scaramuccia published on “Biologicals”
International medical journal hosts review of contract plasma fractionation dynamics
FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin
Announcement by Kedrion Biopharma and Kamada. Regulatory decision expected in August 2017
Humanitarian Factor IX donation to Afghanistan
Kedrion Biopharma confirms its commitment to broaden access to therapies in developing Countries
Kedrion and Kamada seek FDA approval of IgG as a post-exposure treatment
BLA has been submitted on September 1, 2016. Companies planning for decision from FDA in mid-2017
SIPPET Study: interim analysis confirms the original hypothesis
The Study on inhibitors in Hemophilia A is safe to continue after Investigators’ Meeting in San Francisco (Dec 2014)
Investigating inhibitor development in patients with Hemophilia A
Lecture on state-of-the-art of the SIPPET Study presented by P.M. Mannucci, sponsored by Grifols, Kedrion and LFB
Counterfeit RhoGAM Ultra-Filtered PLUS used for preventing HDN found in India
Johnson & Johnson Limited has identified counterfeit RhoGAM Ultra-Filtered PLUS in the state of West Bengal and Uttar Pradesh in India. This issue does not involve any other product manufactured or distributed by Ortho Clinical Diagnostics or Kedrion Biopharma India Pvt. Ltd.
Kedrion collection centers first to be certified in Hungary
Plazmaferezis Állomás Kft achieves international PPTA certification